Toboroz
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
NCT07198074· 3. fázis· National Cancer Institute (NCI)· Forrás
Contact: Pamela J. Stone (principal investigator)
Toboroz
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
NCT07211178· Tempus AI· Forrás
Contact: Kim Neff
Toboroz
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328· 3. fázis· NRG Oncology· Forrás
Contact: James A. Wheeler (principal investigator)
Toboroz
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314· 3. fázis· NRG Oncology· Forrás
Contact: Pamela J. Stone (principal investigator)
Fut, nem toboroz
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
NCT06777433· 2. fázis· Radiopharm Theranostics, Ltd· Forrás
Fut, nem toboroz
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT06500455· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· 3. fázis· NRG Oncology· Forrás
Contact: James A. Wheeler (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Bolanle Adepoju (principal investigator)
Fut, nem toboroz
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
NCT05538897· 1/2. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT05256225· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT05053152· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma
NCT04674683· 3. fázis· HUYABIO International, LLC.· Forrás
Fut, nem toboroz
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
NCT04804644· 3. fázis· NRG Oncology· Forrás
Toboroz
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
NCT04502394· 1/2. fázis· Kartos Therapeutics, Inc.· Forrás
Contact: John Mei
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Contact: Ebenezer Kio, Site 007-943
Toboroz
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052· NRG Oncology· Forrás
Contact: Pamela J. Stone (principal investigator)
Fut, nem toboroz
NCI COVID-19 in Cancer Patients, NCCAPS Study
NCT04387656· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04268550· 2. fázis· SWOG Cancer Research Network· Forrás
Fut, nem toboroz
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NCT04068103· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
NCT04041310· 1/2. fázis· Nouscom SRL· Forrás
Fut, nem toboroz
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04095364· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Jennifer Beeler
Fut, nem toboroz
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE Trial
NCT03371719· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
NCT03137771· 2. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NCT03070886· 2/3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
NCT02954874· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
NCT02595944· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992· 3. fázis· ECOG-ACRIN Cancer Research Group· Forrás
Fut, nem toboroz
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
NCT02193282· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
NCT01220583· 2. fázis· Radiation Therapy Oncology Group· Forrás
Fut, nem toboroz
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
NCT00644228· 3. fázis· National Cancer Institute (NCI)· Forrás